Tag Archive for: Sebela Pharmaceuticals

Destiny Pharma advances strategy against bacteria

Destiny Pharma, one of our longstanding clients, featured in the April 2023 edition of MedNous, the specialist medical research journal. Neil Clark, CEO, and Dr Bill Love, Founder and CSO, sat down with Victoria English to discuss the fantastic progress that has been made with Destiny’s two lead assets, XF-73, a nasal gel for the treatment […]

Destiny Pharma – Audited results for the year ended 31 December 2022

Exclusive North American partnering deal worth up to $570m plus royalties secured for NTCD-M3 Phase 3 development plans finalised for XF-73 nasal following scientific advice from FDA and EMA XF-73 dermal commenced clinically enabling safety study sponsored by US Government’s NIAID New XF research projects initiated in cystic fibrosis and oral mucositis Leadership strengthened with appointment of […]

Destiny Pharma plc – Fundraising to raise up to £8 million

Fundraising to raise up to £8 million Destiny Pharma plc (AIM: DEST) (the “Company” or “Destiny Pharma”), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces a conditional fundraising of up to approximately £8 million (before expenses) comprising a Placing, Subscription and an Open Offer (each as defined below). The […]

Destiny Pharm plc – Agreement with Sebela Pharmaceuticals for NTCD-M3

Exclusive collaboration and co-development agreement for NTCD-M3 with Sebela Pharmaceuticals® worth up to $570m plus royalties Partnership with Sebela will finance the future clinical development and commercialization costs of NTCD-M3 in North America Destiny Pharma retains majority rights for Europe and ROW Key strategic target achieved for NTCD-M3 Brighton, United Kingdom – 24 February 2023 – […]